ResearchHub Logo
Currency
Display format
RSCUSD

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

Authors
Frederick DeweyAlanna MorrisonAlan Shuldiner
Journal
New England Journal of Medicine
Published
March 2, 2016

Abstract

Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1056/nejmoa1510926

License

Unknown License
Inactivating Variants in ANGPTL4 and Risk of Coronary Art... | ResearchHub